ATE498604T1 - Aerosolformulierung umfassend levalbuterol l- tartratsalz - Google Patents

Aerosolformulierung umfassend levalbuterol l- tartratsalz

Info

Publication number
ATE498604T1
ATE498604T1 AT06110646T AT06110646T ATE498604T1 AT E498604 T1 ATE498604 T1 AT E498604T1 AT 06110646 T AT06110646 T AT 06110646T AT 06110646 T AT06110646 T AT 06110646T AT E498604 T1 ATE498604 T1 AT E498604T1
Authority
AT
Austria
Prior art keywords
levalbuterol
aerosol formulation
tartrate salt
tartare
metered dose
Prior art date
Application number
AT06110646T
Other languages
English (en)
Inventor
Paul Mcglynn
Roger Bakale
Craig Sturge
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32507867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE498604(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE498604T1 publication Critical patent/ATE498604T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0484—Alcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0488—Surfactant, e.g. for the lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
AT06110646T 2002-12-10 2003-12-08 Aerosolformulierung umfassend levalbuterol l- tartratsalz ATE498604T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43219502P 2002-12-10 2002-12-10

Publications (1)

Publication Number Publication Date
ATE498604T1 true ATE498604T1 (de) 2011-03-15

Family

ID=32507867

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06110646T ATE498604T1 (de) 2002-12-10 2003-12-08 Aerosolformulierung umfassend levalbuterol l- tartratsalz
AT03786896T ATE324364T1 (de) 2002-12-10 2003-12-08 Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03786896T ATE324364T1 (de) 2002-12-10 2003-12-08 Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators

Country Status (19)

Country Link
US (8) US7256310B2 (de)
EP (3) EP1671942B2 (de)
JP (1) JP4570960B2 (de)
KR (3) KR101166955B1 (de)
AT (2) ATE498604T1 (de)
AU (1) AU2003295695B2 (de)
CA (1) CA2507572C (de)
CY (2) CY1106315T1 (de)
DE (2) DE60304900T2 (de)
DK (3) DK2292584T3 (de)
ES (3) ES2626648T3 (de)
IL (2) IL168739A (de)
MX (1) MXPA05006087A (de)
NO (1) NO331649B1 (de)
NZ (1) NZ541168A (de)
PL (1) PL212725B1 (de)
PT (3) PT2292584T (de)
SI (2) SI1572622T1 (de)
WO (1) WO2004052835A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6466862B1 (en) * 1999-04-19 2002-10-15 Bruce DeKock System for providing traffic information
JP2008512434A (ja) * 2004-09-09 2008-04-24 シプラ・リミテッド ベータ擬似剤の異性体及び抗コリン作用剤を含む医薬組成物
RU2440972C2 (ru) 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
BRPI0517204A (pt) * 2004-12-17 2008-09-30 Cipla Ltd sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol
US8751589B2 (en) 2011-04-13 2014-06-10 Jingle Technologies Llc Systems and methods for transmitting information, alerts, and/or comments to participants based on location information
EP3042892A1 (de) 2015-01-09 2016-07-13 Deva Holding Anonim Sirketi Amorphisierung von Levosalbutamoltartrat
CN106727318A (zh) * 2016-12-22 2017-05-31 山东京卫制药有限公司 一种气雾剂及其制备方法
CN115209872B (zh) * 2020-03-19 2024-08-02 广州谷森制药有限公司 含有酒石酸左旋沙丁胺醇的可吸入制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
GB8828477D0 (en) † 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5345980A (en) 1989-09-21 1994-09-13 Glaxo Group Limited Method and apparatus an aerosol container
US5362755A (en) 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5255183A (en) * 1990-05-29 1993-10-19 Interactive Voice Data System Inc. Telephone-based personnel tracking system
ATE339952T1 (de) 1991-06-10 2006-10-15 Schering Corp Fluorchlorkohlenwasserstofffreie aerosolformulierungen
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5399765A (en) 1994-05-23 1995-03-21 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
AU710382B2 (en) * 1995-04-14 1999-09-16 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
US5603918A (en) 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB9806462D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
WO2000006121A1 (de) * 1998-07-24 2000-02-10 Jago Research Ag Medizinische aerosolformulierungen
ES2193726T3 (es) * 1998-08-04 2003-11-01 Jago Res Ag Formulaciones de aerosol medicinales.
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
CN1173929C (zh) 1999-10-19 2004-11-03 中国科学院成都有机化学研究所 光学纯肾上腺素类β-激动剂的组合拆分制备法
US6451289B2 (en) 2000-03-24 2002-09-17 Sepracor Inc. Albuterol formulations
GB0030171D0 (en) 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol
CA2442415C (en) * 2001-03-30 2010-07-20 Jagotec Ag Medical aerosol formulations
DE10120531A1 (de) * 2001-04-26 2002-10-31 Basf Ag Neue Reaktivfarbstoffe und deren Verwendung zum Färben von Substraten, welche nucleophile Gruppen enthalten
CN1206205C (zh) * 2001-04-26 2005-06-15 中国科学院成都有机化学研究所 R－沙丁胺醇酒石酸盐的制备方法

Also Published As

Publication number Publication date
US8765153B2 (en) 2014-07-01
ES2361172T5 (es) 2014-09-22
PL377336A1 (pl) 2006-01-23
DK1671942T4 (da) 2014-09-22
ES2263051T3 (es) 2006-12-01
ATE324364T1 (de) 2006-05-15
US20080119564A1 (en) 2008-05-22
CY1106315T1 (el) 2011-10-12
SI1671942T1 (sl) 2011-04-29
EP1671942B2 (de) 2014-07-23
US20150071969A1 (en) 2015-03-12
CY1111330T1 (el) 2015-08-05
EP2292584A1 (de) 2011-03-09
US20040115136A1 (en) 2004-06-17
US7256310B2 (en) 2007-08-14
EP2292584B1 (de) 2017-03-01
US20100272654A1 (en) 2010-10-28
US20130028845A1 (en) 2013-01-31
IL212369A0 (en) 2011-06-30
EP1572622A1 (de) 2005-09-14
KR20100080865A (ko) 2010-07-12
EP1671942B1 (de) 2011-02-16
PT1671942E (pt) 2011-05-11
ES2361172T3 (es) 2011-06-14
IL168739A (en) 2011-06-30
DK1671942T3 (da) 2011-04-26
NZ541168A (en) 2008-10-31
CA2507572A1 (en) 2004-06-24
CA2507572C (en) 2011-04-19
DE60336089D1 (de) 2011-03-31
PL212725B1 (pl) 2012-11-30
JP4570960B2 (ja) 2010-10-27
MXPA05006087A (es) 2005-09-30
AU2003295695B2 (en) 2009-08-20
SI1572622T1 (sl) 2006-10-31
NO331649B1 (no) 2012-02-13
DK1572622T3 (da) 2006-08-28
NO20053339D0 (no) 2005-07-08
US20180222845A1 (en) 2018-08-09
AU2003295695A1 (en) 2004-06-30
US20160368858A1 (en) 2016-12-22
NO20053339L (no) 2005-09-07
US20130236515A1 (en) 2013-09-12
KR20050088307A (ko) 2005-09-05
ES2626648T3 (es) 2017-07-25
KR20080103614A (ko) 2008-11-27
SI1671942T2 (sl) 2014-10-30
IL212369A (en) 2013-08-29
DE60304900T2 (de) 2006-10-19
EP1572622B1 (de) 2006-04-26
KR101166955B1 (ko) 2012-07-19
WO2004052835A1 (en) 2004-06-24
DE60304900D1 (de) 2006-06-01
PT1572622E (pt) 2006-08-31
PT2292584T (pt) 2017-06-12
JP2006509802A (ja) 2006-03-23
EP1671942A1 (de) 2006-06-21
DK2292584T3 (en) 2017-05-01

Similar Documents

Publication Publication Date Title
ATE415994T1 (de) Vorabgefülltes dosismagazin für einen atmungsbetätigten trockenpulverinhalator
CY2009009I2 (el) Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
IL174496A0 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
BR0309117A (pt) Kit de inalação compreendendo pó inalável de tiotropium
SG149043A1 (en) N,n-dihalogenated amino acids and derivatives
IL163844A0 (en) Pressurised metered dose inhalers containing solutions of beta-2 agonists
GB0420888D0 (en) Compounds and uses
HK1129111A1 (en) Tiotropium salts, pharmaceutical formulations containing the salts and the use thereof
IL212369A0 (en) A metered dose inhaler comprising a canister containing an aerosol formulation comprising levalbuterol l-tartrate, and use of levalbuterol l-tartrate in the manufacture of said metered dose inhaler for treating bronchospasm.
DK1229953T3 (da) Inhalationsaktiveret anordning til anvendelse med inhalatorer med afmålt dosis (MDI)
GB0328630D0 (en) Metered dose inhalation preparations
IL182834A0 (en) Sulfonamido-macrocycles and the salts thereof, a pharmaceutical composition comprisng these compounds, the method of preparing and the use thereof
BRPI0507225A2 (pt) formulações estáveis de solução farmacêutica para inaladores pressurizados de dose medida
HK1085918A1 (en) Pulverulent formulation for inhalation containing tiotropium
DE50309414D1 (de) Aerosolformulierung für die inhalation enthaltend tiotropiumbromid
UY27445A1 (es) Nuevo medicamentos para la inhalación.
HK1103280A1 (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers
ZA200606577B (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers
GB0226274D0 (en) Metered dose inhalation preparations
AU2005907076A0 (en) A stand-alone mechanical counter that fits onto existing pressurised Metered Dose Inhalers(pMDIs) used to deliver medication to the lungs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1671942

Country of ref document: EP